ArticleClinical rheumatology2026
GPR56 and CD319 identify distinct cytotoxic-associated DP and DN T-cell subsets in early systemic lupus erythematosus.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo characterize the expression patterns of GPR56 and CD319 across peripheral blood T-cell subsets, including CD4⁺, CD8⁺, double-positive (DP), and double-negative (DN) T-cells, and to evaluate their potential diagnostic value and clinical relevance in systemic lupus erythematosus (SLE).
methodsPeripheral blood samples from 34 newly diagnosed, treatment-naïve SLE patients and 29 age- and sex-matched healthy controls were analyzed by flow cytometry. The frequencies of GPR56⁺ and CD319⁺ cells within CD4⁺, CD8⁺, DP, and DN T-cell subsets, together with their co-expression of cytotoxic molecules granzyme B and perforin, were evaluated. Clinical parameters, autoantibody profiles, complement levels, and hematological indices were collected. Group comparisons, correlation analyses, receiver operating characteristic (ROC) analyses, and multivariable logistic regression models incorporating eight GPR56- and CD319-associated parameters were performed.
resultsGPR56 and CD319 were preferentially expressed on DP and DN T-cells and strongly associated with cytotoxic effector molecules. Compared with healthy controls, SLE patients exhibited increased frequencies of GPR56⁺ cells within CD4⁺CD8⁻, DP, and CD4⁻CD8⁺ T-cell subsets, whereas CD319⁺ cells displayed subset-dependent alterations, with increased frequencies in CD4⁺CD8⁻ and CD4⁻CD8⁺ T-cells but decreased frequencies in DN T-cells. GPR56⁺ and CD319⁺ CD4⁺CD8⁻ T-cells were positively associated with anti-Sm and anti-U1RNP antibodies, while reduced CD319⁺ DN T-cells correlated with lower serum C3 levels. Among individual parameters, CD319⁺ DN T-cells showed the highest diagnostic performance for early SLE identification. A combined logistic regression model incorporating all eight parameters achieved excellent discrimination between SLE patients and healthy controls (AUC = 0.926).
conclusionGPR56 and CD319 identify cytotoxic-associated DP and DN T-cell populations with distinct alterations in newly diagnosed SLE. Integrated assessment of GPR56- and CD319-associated T-cell subsets may provide complementary biomarkers for early SLE identification and warrants further validation in larger cohorts.
Indexed as
Identifiers
42745124What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.